Sacral Nerve Stimulation - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The sacral nerve stimulation market size was valued at USD 1.64 billion in 2025 and estimated to grow from USD 1.81 billion in 2026 to reach USD 2.94 billion by 2031, at a CAGR of 10.18% during the forecast period (2026-2031). This report is Segmented by Product (External Sacral Nerve Stimulation Systems and Implantable Sacral Nerve Stimulation Systems), Applications (Urge Urinary Incontinence, Urinary & Fecal Incontinence, Chronic Anal Fissure, and More), End-User (Hospitals, Ambulatory Surgical Centers, and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Sacral Nerve Stimulation Market Trends and Insights

Rising Prevalence Of Overactive Bladder & Urge/Fecal Incontinence

Global aging and rising obesity levels continue to enlarge the clinical pool of patients who do not respond to behavioral therapy or pharmacologics. National Health and Nutrition Examination Survey data show urinary incontinence symptoms in 61.8% of women, a marked uptick versus prior cycles. Overactive bladder affects 27.4% of mixed-gender cohorts according to recent cross-sectional studies, with nocturia singled out as the most disruptive symptom to daily living. As symptom burden rises, neuromodulation gains traction when first-line antimuscarinics or β3-agonists fail. Clinicians now position sacral nerve stimulation earlier in care algorithms, particularly for patients aiming to curb anticholinergic side effects. The mounting prevalence thus exerts a sustained pull on procedure volumes over the long term.

Favourable Reimbursement & Coverage Expansions

The U.S. Centers for Medicare & Medicaid Services introduced explicit HCPCS codes for both trial and permanent implants, narrowing administrative ambiguity and leveling payment across provider sites. The 2026 proposed ASC Covered Procedures List adds hundreds of codes that could further migrate volumes to lower-cost outpatient centers. Private payers are aligning, routinely covering permanent implants after ≥50% symptom improvement during the trial. Outside the United States, Australia’s Prostheses List and Japan’s accelerated review channels now reimburse next-generation rechargeable systems, an approach that trims patient out-of-pocket spends and accelerates hospital adoption. Collectively, these policies raise the accessible patient pool in both developed and emerging economies.

Device-Related Adverse Events & High Revision Rates

Single-center audits of 155 implants documented 38.2% reoperation within five years, driven by lead migration, pain, and hardware failure. Multicenter colon-rectal cohorts noted 35.5% revision or explant despite preserved efficacy, pointing to durability rather than therapeutic failure issues. Australian regulator surveillance shows roughly 4 explants per 10 spinal cord stimulators annually, stoking clinician caution when counseling candidates. While next-generation hardware should trim mechanical failures, the near-term perception of high revision risk persists, dampening penetration in risk-averse markets.

Other drivers and restraints analyzed in the detailed report include:

• Miniaturised, MRI-Compatible, Rechargeable Implant Designs
• AI-Enabled Closed-Loop Neuromodulation Algorithms
• High Implant Costs & Limited Surgeon Training Outside Tier-1 Centres

Segment Analysis

Implantable systems captured 85.92% of the sacral nerve stimulation market in 2025 on the back of superior efficacy and convenience over external options. This product class promises uninterrupted therapy for 10-15 years, eliminating compliance gaps that can erode outcomes in external trials. Rechargeable chemistries now deliver monthly charging routines of roughly 60 minutes, a compromise most patients accept when weighed against reoperations for battery replacement. Hospital procurement committees lean toward implantable platforms as they spread capital cost over extended life cycles, boosting return on investment.

External systems, though accounting for a modest slice of 2025 revenues, are logging a 12.44% CAGR and serve a critical role in patient screening. Smartphone-linked controllers and cloud dashboards enable clinicians to measure symptom logs remotely, refining candidate selection and cutting failed permanent implants. Regulatory bodies cemented this workflow by carving out dedicated reimbursement codes, giving payers an auditable pathway from diagnosis to trial to implant. In emerging markets where procedural budgets run tight, external devices also satisfy unmet need among patients unwilling or unable to fund full surgery.

Complete Report Scope:

• By Product Type
  • External Sacral Nerve Stimulation Systems
  • Implantable Sacral Nerve Stimulation Systems
• By Application
  • Urge Urinary Incontinence
  • Urinary & Fecal Incontinence (Mixed)
  • Chronic Anal Fissure
  • Other Neuromodulation-responsive Disorders
• By End-User
  • Hospitals
  • Ambulatory Surgical Centres
  • Specialty Continence Clinics
  • Others
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America retained 45.58% of 2025 sales, cemented by three decades of physician familiarity and a mature reimbursement backbone that pays for both trial and permanent stages. U.S. procedure growth now revolves around technology refresh cycles - clinics upgrading to MRI-safe, rechargeable, or closed-loop platforms - as opposed to expanding the naïve patient base. Canada mirrors these maturation dynamics but faces province-by-province funding variability that introduces waiting lists in less-populated regions. Mexico’s private hospital chains are piloting sacral nerve stimulation market offerings to capture inbound medical tourism, enriching the regional mix.

Europe combines broad statutory coverage with stringent Medical Device Regulation audits that elevate quality thresholds yet elongate filings. Germany and France are the volume anchors where high-density specialist centers coexist with aging demographics prone to incontinence. The United Kingdom is investing in community continence clinics aimed at earlier identification of candidates, potentially shifting initiation of neuromodulation further upstream in the care pathway.

Asia-Pacific is the growth pacesetter at 12.29% CAGR, fueled by Australia’s 2024 approval of Axonics’ fourth-generation system and Japan’s expedited review designations for breakthrough neuromodulation devices. Both countries pair regulatory agility with reimbursement, catalyzing procedure ramp-up. In China and India, private hospitals are opting for external trial systems first, a cost-savvy route that seeds future implant demand. Coupled with the region’s swift urbanization and expanding middle class healthcare budgets, these moves underpin long-run upside for the sacral nerve stimulation market.

Rest-of-world jurisdictions such as Latin America and the Middle East remain nascent but opportunistic. Select Gulf states fund implants for nationals traveling abroad, while flagship academic hospitals in Brazil and Saudi Arabia are enrolling in multinational closed-loop trials to leapfrog legacy technology. Overall, accelerating global diffusion combined with local reimbursement gains fortifies the international expansion narrative.

List of Companies Covered in this Report:

• Medtronic
• Axonics Inc.
• Abbott Laboratories
• Boston Scientific
• Laborie Medical Technologies
• Nevro
• Johnson & Johnson
• LivaNova plc
• Neuspera Medical
• BlueWind Medical
• Valencia Technologies
• EBT Medical
• Synapse Biomedical
• Inspire Medical Systems
• Biomedical Life Systems
• Nuvectra Corp.
• NeuroPace

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support